Device Trial Radar · NCT03154450
EncoreAnywhere Use in Motor Neurone Disease
Last checked: Nov 19, 2026Latest source record: Dec 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Jan 21, 2016
Primary completion
Apr 1, 2017
Study completion Apr 1, 2017
Sponsor
- Lead sponsor
- Sheffield Teaching Hospitals NHS Foundation TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 16, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Motor neurone disease is a progressive incurable disease causing weakness and paralysis of muscles. Respiratory failure is the most common cause of death in motor neurone disease. Patients with respiratory failure use a machine that supports breathing using a mask and ventilator (non-invasive ventilation: NIV) and using it for more than five hours per night has been shown to prolong life and improve symptoms such as poor sleep and breathlessness. NIV is however, challenging to use and some patients are unable to adhere to the required regime meaning they fail to gain benefit. Timely support is important to help individuals overcome early hurdles and barriers to using becoming regular NIV users. The Philips EncoreAnywhere is a system that allows continuous monitoring of the use and effectiveness of ventilation and allows instant adjustment of ventilator settings. The aim of this project is to explore if "real time" feedback and support, as well as remote changes to NIV settings using the EncoreAnywhere system could increase the number of individuals successfully using NIV. This project also aims to explore the impact of using EncoreAnywhere on the process of initiation of NIV, on both patients and staff. Patients starting NIV at the Sheffield MND care centre will be provided with the standard ventilator plus a Philips modem for the first three months of use. In half the patients clinicians will be able to use the EncoreAnywhere system to review patients' use of NIV, make adjustments and give feedback. In the other half, the data will be collected but not available to the clinical team. Clinical data will be collected as part of usual care: adherence, clinical encounters and resource use and patients will be asked to complete questionnaires at baseline, one month and three months. This will allow the care team to predict the potential impact on the service and on clinical care. This is a small pilot, feasibility study, and if the study is deemed feasible, a further larger randomized controlled trial is planned. The study will last for a maximum of 12 months, recruiting up to 40 patients.
Conditions
- Motor Neuron Disease
Interventions
EncoreAnywhere with data available to reviewDevice
Encore Anywhere will be installed and available for review by the clinical team
EncoreAnywhere with no data available to reviewDevice
Encore Anywhere will be installed but not available for review by the clinical team
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adherence to non-invasive ventilation (NIV)Time frame: One week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Royal Hallamshire Hospital
Sheffield, South Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.